Regencell Bioscience Extends Insider Stock Lock-Up to April 2027

Regencell Bioscience ( (RGC) ) has issued an update.

On February 13, 2026, Regencell Bioscience announced that all employees and directors who previously received stock options have agreed to extend their lock-up commitments for an additional 12 months, through April 20, 2027. During this period, 100% of employees’ shares and vested options and 82% to 92% of directors’ shares and vested options will remain restricted, following earlier lock-up agreements that already ran until April 20, 2026.

The extended lock-up, formalized in a fifth amendment to prior undertakings, signals internal confidence and is likely to limit insider selling pressure over the coming year. For shareholders, the move may help support share price stability and align management and employee incentives with longer-term company performance, while modestly increasing future liquidity visibility once the new lock-up expires.

More about Regencell Bioscience

Regencell Bioscience Holdings Limited is a Hong Kong-based biotechnology company whose shares trade in the U.S. as a foreign private issuer. The company focuses on developing and commercializing treatments in the bioscience and healthcare space, with equity compensation in the form of stock options playing a role in its employee and director incentives.

Average Trading Volume: 485,459

Technical Sentiment Signal: Buy

Current Market Cap: $13.21B

See more data about RGC stock on TipRanks’ Stock Analysis page.